392P A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer

J. Yang,J. Zhou, M. li,Z-Y. Zhang,Y. Cheng, D.H. Chu, H. Pan,B. Wang,G. Chen,K. Wang, L. Jiang,Y. Hu, J. Shi, A-M. Hui,Y. Zhou, Z. Wu,J. Sun,Y. Tan, X. Xiang,Y-L. Wu

Annals of Oncology（2022）

引用 0|浏览12

暂无评分

摘要

ROS1 fusions (ROS1+) are enriched in 1-2% of non-small cell lung cancer (NSCLC) cases. SAF-189s is a novel, next-generation ALK/ROS1 inhibitor which overcomes multiple resistance mutations. We explored the efficacy and safety of SAF-189s in phase (Ph) 2 study in patients (pts) with ROS1 fusion NSCLC, with or without ROS1 inhibitor treatment.

查看译文

关键词

lung cancer,fusion-positive,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要